CFDE Data Portal | Search ALG1L1P

	Label	Description
	ALG1L1P Gene (Entity type)	ENSG00000291096 - ALG1 like 1, pseudogene
	GSE173116 GSE173118 ML-7 8 v 5 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE208350 H-7 Huh-7 JHH-7 4 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE115384 CELSR2 knockdown 0 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216540 fulvestrant 10 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE149768 hypoxanthine 3 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 cisplatin 11 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE142357 HDAC3 inhibition 1 v 3 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE85880 GSE85881 tretinoin cardiac muscle cell 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236502 paclitaxel 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS

ALG1L1P

ENSG00000291096 - ALG1 like 1, pseudogene

GSE173116 GSE173118 ML-7 8 v 5 human dn

A Gene Set from LINCS

GSE208350 H-7 Huh-7 JHH-7 4 v 3 human up

A Gene Set from LINCS

GSE115384 CELSR2 knockdown 0 v 3 human up

A Gene Set from LINCS

GSE216540 fulvestrant 10 v 6 human dn

A Gene Set from LINCS

GSE149768 hypoxanthine 3 v 1 human up

A Gene Set from LINCS

GSE216043 cisplatin 11 v 1 human dn

A Gene Set from LINCS

GSE142357 HDAC3 inhibition 1 v 3 human up

A Gene Set from LINCS

GSE85880 GSE85881 tretinoin cardiac muscle cell 0 v 1 human up

A Gene Set from LINCS

GSE236502 paclitaxel 1 v 3 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.